High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results
| Autor: | Mohammed Abd Algaber, Heba Omar, Yasmeen Abd El Latif, Mohamed El Kassas, Kadry Elsaeed, Magdy El-Serafy, Wahid Doss, Hesham El Halwagy, Shimaa Afify, Adel El Tahan, Mohamed Alboraie |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Cyclopropanes Liver Cirrhosis Male medicine.medical_specialty Genotype Proline Sustained Virologic Response Sofosbuvir Lactams Macrocyclic Hepacivirus Antiviral Agents 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Virology Internal medicine Ombitasvir/paritaprevir/ritonavir Ribavirin medicine Humans Anilides Prospective Studies 030212 general & internal medicine Prospective cohort study Fatigue Sulfonamides Ritonavir Intention-to-treat analysis business.industry Anemia Valine Hepatitis C Chronic Middle Aged medicine.disease Ombitasvir Infectious Diseases chemistry Paritaprevir Drug Therapy Combination Female 030211 gastroenterology & hepatology Viral hepatitis business medicine.drug |
| Zdroj: | Journal of Medical Virology. 94:667-674 |
| ISSN: | 1096-9071 0146-6615 |
| Popis: | INTRODUCTION AND AIMS Treatment of hepatitis C virus (HCV) genotype 4 patient with fixed dose combination of ombitasvir-paritaprevir-ritonavir plus ribavirin (OBV/rPTV/RBV) has been proven efficacy and safety in many clinical trials. The current study reports the efficacy and safety of OBV/rPTV/RBV (for treatment-naive), and OBV/rPTV/RBV/sofosbuvir (SOF) (for treatment-experienced), in chronic HCV genotype 4 patients in real life settings. METHODS Prospective cohort study including all adult chronic HCV genotype 4 patients who were scheduled to receive OBV/rPTV/RBV ± SOF for 12 or 24 weeks in New Cairo Viral Hepatitis Treatment Center. The primary efficacy endpoint was a virologic response at posttreatment week 12 (SVR12). Changes in hematological parameters, liver biochemical profile and fibrosis-4 index (FIB-4), as well as clinical and laboratory adverse events (AEs) across follow up visits (week 4, end of treatment [EOT], and SVR12), were recorded. RESULTS Our study included 325 patients (age; 47.63 ± 12.63 years, 55.38% [n = 180] men). Most of the included patients (89.85%, n = 292) were treatment naive and only 7% (n = 23) had liver cirrhosis. Overall, SVR12 was attained by 98.44% (316 of 321) of the patients; 97.15% (307 of 316) of patients who received 12 weeks of OBV/rPTV/RBV ± SOF and 100% (9 of 9) of patients who received 24 weeks of OBV/rPTV/RBV as assessed by modified intention to treat analysis. There was a significant improvement of baseline alanine aminotransferase, aspartate aminotransferase, hemoglobin, FIB-4 at SVR12 (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text